StreetInsider.com News Articles

Citi Starts SAB Biotherapeutics (SABS) at Buy

Fri, 22 May 2026 05:08:32 -0400

Citi analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) with a Buy rating and a price target of $11.00.

For an analyst ratings summary and ratings history on SAB Biotherapeutics click here. For more ratings news on SAB Biotherapeutics click here.

Shares of SAB Biotherapeutics closed at $3.81 yesterday.

Jefferies Starts SAB Biotherapeutics (SABS) at Buy

Wed, 20 May 2026 03:18:09 -0400

Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) with a Buy rating and a price target of $11.00.

The analyst comments: “SABS is developing potentially the first therapy for Stage 3 T1D to preserve C peptide and delay progression of disease in recently diagnosed pts who have only had the option of SOC insulin for last 100+ years. We see SABS’s lead program, SAB-142, as having the pot'l to meaningfully alter the Tx landscape for T1D to preserve endogenous C-peptide production and thus reduce the risk of long term T1D complications such as kidney disease and diabetic retinopathy.

Jefferies Starts SAB Biotherapeutics (SABS) at Buy

Wed, 20 May 2026 03:18:09 -0400

Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) with a Buy rating and a price target of $11.00.

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504581.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 15 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260515/26504581.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Caligan Partners LP

Fri, 15 May 2026 11:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26502070.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Caligan Partners LP

Fri, 15 May 2026 11:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26502070.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26498902.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26498902.html

SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright

Tue, 12 May 2026 12:09:56 -0400

(Updated - May 12, 2026 12:09 PM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $10.00 (from $7.00) while maintaining a Buy rating.

The analyst comments "1Q26 financial recap; increasing PT to $10 on lower diluted shares outstanding. SAB BIO had 1Q26 total operating expenses of $20.0M, which increased when compared to 4Q25 operating expenses. This was likely driven by increased spending associated with enrolling patients in the Phase 2b SAFEGUARD trial for SAB-142 in Stage 3 T1D. Basic and diluted EPS in 1Q26 was ($0.35). We estimate expenses to moderately increase in 2026

SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright

Tue, 12 May 2026 12:09:56 -0400

(Updated - May 12, 2026 12:09 PM EDT)

H.C. Wainwright analyst Emily Bodnar raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $10.00 (from $7.00) while maintaining a Buy rating.

Form 10-Q SAB Biotherapeutics, For: Mar 31

Tue, 12 May 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260512/26473096.html

Form 10-Q SAB Biotherapeutics, For: Mar 31

Tue, 12 May 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260512/26473096.html

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

Tue, 12 May 2026 07:30:57 -0400

SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.

The company reported a net loss of $18.9 million for the quarter ended March 31, 2026, compared to a $5.2 million loss in the same period last year. Research and development expenses increased to $13.4 million from $7.7 million year-over-year, driven by investments in the SAB-142 program.

SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway

SAB Biotherapeutics reports Q1 2026 results, enrollment progress

Tue, 12 May 2026 07:30:57 -0400

SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.

SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Tue, 12 May 2026 07:30:00 -0400

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes

Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities

Conference call today at 8:30 AM ET

MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: